Clay Siegall is an entrepreneur and scientist. He has a B.S. in Zoology from the University of Maryland and achieved a PhD.D. in Genetics from George Washington his career Clay has attained some awards one of them being the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. Clay Siegall has been in the biotechnology industry for many years and thus achieved so much. He co-founded Seattle Genetic in 1998.He is currently the President, CEO and chairman of the board of members at Seattle Genetic Company.

Biotechnology is simply the use of different microorganisms to conduct certain engineering procedures, to produce drugs and artificial is all about the invention of technology in science. Seattle Genetic is a biotechnology that specifically targets cancer patients. They work on producing the best antibody drug conjugates (ADC). Clay Siegall and his team have worked day in day out to make sure that cancer patients get the best treatment they need to move on. The company’s first product, Adcetris, has been established in more than 60 countries around the world.

Under the positive influence of Clay Siegall, different clinical developments are using over 20 ADCs of Seattle Genetic knowledge. The financial status of the company has also massively increased due to the leadership of Clay has recently hit $330 million in both the public and private sector. Adcetris the company’s first product has so far been used to treat over 15,000 patients suffering from Lymphoma worldwide.

Apart from Adcetris, Seattle Genetic Company has other advancements to be used in clinical programs, they include SGN-CD19A in non-Hodgkin lymphoma and SGN-CD33A in acute myeloid leukemia. The results are progressive, therefore Clay Siegall and The company hopes for much more cancer treating therapies to enhance the lives of the patients. Currently Seattle Genetics has collaborated with related companies to produce more cancer treatment. The companies Clay Siegall joined are Alder Bio-pharmaceuticals, Mirna Therapeutics and Ultragenyx. He is a board of directors of the companies.

Categories: Cancer Research

Comments are Closed on this Post